Back
BioCryst Pharmaceuticals, Inc. 10K Form
Buy
59
BCRX
BioCryst Pharmaceuticals, Inc.
Last Price:
$7.84
Seasonality Move:
8.4%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | BCRX/BioCryst Pharmaceuticals, Inc. Quarterly |
| 2023-11-08 | 10Q | BCRX/BioCryst Pharmaceuticals, Inc. Quarterly |
| 2023-08-07 | 10Q | BCRX/BioCryst Pharmaceuticals, Inc. Quarterly |
| 2023-05-08 | 10Q | BCRX/BioCryst Pharmaceuticals, Inc. Quarterly |
| 2022-11-04 | 10Q | BCRX/BioCryst Pharmaceuticals, Inc. Quarterly |
| 2022-08-05 | 10Q | BCRX/BioCryst Pharmaceuticals, Inc. Quarterly |
Receive BCRX News And Ratings
See the #1 stock for the next 7 days that we like better than BCRX
BCRX Financial Statistics
Sales & Book Value
| Annual Sales: | $450.7M |
|---|---|
| Cash Flow: | $39.8M |
| Price / Cash Flow: | 35.44 |
| Annual Sales: | $-1.84 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.04730 |
|---|---|
| Net Income (TTM): | $-8.8M |
| Gross Margin: | $437M |
| Return on Equity: | 0% |
| Return on Assets: | -1.86% |
BioCryst Pharmaceuticals, Inc. Earnings Forecast
Key BioCryst Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 31 years for BCRX is 96.95%.
-
The Selling, General & Administrative Expenses for BCRX have been equal to 59.05% of Gross Profit Margin.
-
The Research & Development expenses have been 38.47% of Revenue.
-
The Net Earning history of BCRX is -19.72% of Total Revenues.
-
Per Share Earnings over the last 31 years have been positive in 14 years.
BioCryst Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BCRX |
| CUSIP: | 09058V |
| Website: | biocryst.com |
Debt
| Debt-to-Equity Ratio: | -1.76 |
|---|---|
| Current Ratio: | 1.87 |
| Quick Ratio: | 1.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 26.77 |
BCRX Technical Analysis vs Fundamental Analysis
Buy
59
BioCryst Pharmaceuticals, Inc. (BCRX)
is a Buy
Is BioCryst Pharmaceuticals, Inc. a Buy or a Sell?
-
BioCryst Pharmaceuticals, Inc. stock is rated a BuyThe current BioCryst Pharmaceuticals, Inc. [BCRX] share price is $7.83. The Score for BCRX is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.